macular Degeneration

CBMS holds the exclusive license to a patented technology developed by Eugene Levin, Ph.D. while at The Scripps Research Institute. CBMS has licensed this small protein therapeutic (LD22-4) from OTHI., for the treatment of the wet form of age-related macular degeneration (AMD). 

Wet AMD is one of the leading causes of severe vision loss and blindness in the adult population.  Because LD22-4 directly targets a fundamental requirement for the proliferation of blood vessels , i.e. cell migration, we believe that its mode of action is distinct from other drugs that are on the market or that are in development by other biotechnology or pharmaceutical companies.

 “We have already demonstrated in several different animal models that angiogenesis is dramatically suppressed in the presence of LD22-4,” said Eugene Levin, Ph.D., He added, “The proposed method of administration of LD22-4, intravitreal injection, is commonly used to administer ophthalmic drugs and generally accepted by patients facing the prospect of blindness and other serious back of the eye complications.  However we believe that our therapy  can be adopted to offer a less invasive method of administration that  may have a competitive advantage over one administered by intravitreal injection.”

 LD22-4 is currently in preclinical studies and a patent application has been filed for the therapeutic use of this product.

design by: www.idott.com